Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (CLEan)
Brief description of study
- Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE)
- Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity)
- Assess the effect of SAR443122 on CLE induced itch and overall pain
- Assess the effect of SAR443122 on the proportion of disease activity responders compared to placebo
- Assess the effect of SAR443122 on the CLASI components score
- Assess the effect of SAR443122 on the Investigator's global assessment for CLE (IGA-CLE)
- Assess oral cavities for patients with oral lesions
- Assess the disease specific quality of life (QoL)
- Assess the safety and tolerability of SAR443122 in patients with CLE
- Assess the pharmacokinetics (PK) exposure of SAR443122 in patients with CLE
Detailed description of study
Total study duration per participant will be up 20 weeks including:
- A screening period of up to 4 weeks
- A treatment period of 12 weeks
- A post treatment follow-up period of 4 weeks
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Cutaneous Lupus Erythematosus
Age: Between 18 Years - 80 Years
Gender: Male or Female
Inclusion criteria :
- Participants with cutaneous lupus erythematosus either in the form of discoid/chronic cutaneous lupus erythematosus or subacute cutaneous lupus erythematosus for at least 3 months before Screening.
- Participants with histologically confirmed and documented diagnosis within one year prior to Screening or during Screening period prior to randomization.
- Active cutaneous lupus erythematosus skin lesions and a Cutaneous Erythematosus.
- Disease Area and Severity Index activity (CLASI-A) ≥10 both at Screening and Baseline.
- Participant who is candidate for systemic treatment per Investigator's judgement.
- Systemic lupus erythematosus according to the 2012 SLICC criteria with major organ involvement.
- Suspected or proven drug induced lupus erythematosus, including patients with positive antihistone autoantibody tests.
- Autoimmune disease(s) other than systemic lupus erythematosus.
- Active skin diseases that may interfere with the study or study assessments.
- Exclusion related to tuberculosis, non-tuberculous mycobacterial infections, HIV, HBV, HCV, Herpes zoster, COVID-19 and other recurrent or recent serious infections.
- Prolonged QTcF ≥ 450 ms (by Fridericia formula) or clinically significant findings on electrocardiogram (ECG).
- Cannot avoid excessive UV exposure 4 weeks prior to baseline and during the study. Routine sun exposure through work are permitted but requires the use of sun block to sun exposed areas for at least 4 weeks prior to baseline and during the study.
- Concomitant treatment with topical immunosuppressants beyond a stable regimen of low to medium potency topical corticosteroids and/or topical calcineurin inhibitors during the study and two weeks before baseline visit.
- Initiation and/or changes in dosage of chloroquine/hydroxychloroquine within 12 weeks prior to Screening visit (or during Screening period) and/or the dose exceeding 2.3 mg/kg/day for chloroquine or 400 mg/day for hydroxychloroquine.
- Systemic treatments for cutaneous or systemic lupus erythematosus or immunosuppressive therapy for autoimmune disease other than the study medication.
- Systemic corticosteroids treatment <4 weeks before baseline visit.
- Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study.
- Laboratory abnormalities at the Screening visit.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Updated on 17 Feb 2023 . Study ID: NCT04781816
Find a site
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting